|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
5
|
Yan BC, Mackinnon AC and Al-Ahmadie HA:
Recent developments in the pathology of renal tumors: morphology
and molecular characteristics of select entities. Arch Pathol Lab
Med. 133:1026–1032. 2009.PubMed/NCBI
|
|
6
|
Yu ZH, Zhang Q, Wang YD, Chen J, Jiang ZM,
Shi M, Guo X, Qin J, Cui GH, Cai ZM, et al: Overexpression of
cyclooxygenase-1 correlates with poor prognosis in renal cell
carcinoma. Asian Pac J Cancer Prev. 14:3729–3734. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
8
|
Zisman A, Pantuck AJ, Wieder J, Chao DH,
Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk
group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue YJ, Xiao RH, Long DZ, Zou XF, Wang XN,
Zhang GX, Yuan YH, Wu GQ, Yang J, Wu YT, et al: Overexpression of
FoxM1 is associated with tumor progression in patients with clear
cell renal cell carcinoma. J Transl Med. 10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choi YD, Kim KS, Ryu S, Park Y, Cho NH,
Rha SH, Jang JJ, Ro JY, Juhng SW and Choi C: Claudin-7 is highly
expressed in chromophobe renal cell carcinoma and renal oncocytoma.
J Korean Med Sci. 22:305–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garzon R, Pichiorri F, Palumbo T,
Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder
H, et al: MicroRNA gene expression during retinoic acid-induced
differentiation of human acute promyelocytic leukemia. Oncogene.
26:4148–4157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao Y, Charlesworth J, Nair V and Watson
M: MicroRNA expression profiles in avian haemopoietic cells. Front
Genet. 4:1532013.PubMed/NCBI
|
|
13
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
15
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoo AS, Staahl BT, Chen L and Crabtree GR:
MicroRNA-mediated switching of chromatin-remodelling complexes in
neural development. Nature. 460:642–646. 2009.PubMed/NCBI
|
|
17
|
le Sage C, Nagel R, Egan DA, Schrier M,
Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, et
al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and
miR-222 promotes cancer cell proliferation. EMBO J. 26:3699–3708.
2007.PubMed/NCBI
|
|
18
|
Zhang H, Li Y and Lai M: The microRNA
network and tumor metastasis. Oncogene. 29:937–948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sachdeva M and Mo YY: miR-145-mediated
suppression of cell growth, invasion and metastasis. Am J Transl
Res. 2:170–180. 2010.PubMed/NCBI
|
|
20
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lakshmipathy U, Love B, Adams C,
Thyagarajan B and Chesnut JD: Micro RNA profiling: an easy and
rapid method to screen and characterize stem cell populations.
Methods Mol Biol. 407:97–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Michael MZ, O’ Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
23
|
Doberstein K, Steinmeyer N, Hartmetz AK,
Eberhardt W, Mittelbronn M, Harter PN, Juengel E, Blaheta R,
Pfeilschifter J and Gutwein P: MicroRNA-145 targets the
metalloprotease ADAM17 and is suppressed in renal cell carcinoma
patients. Neoplasia. 15:218–230. 2013.PubMed/NCBI
|
|
24
|
Ozen M, Creighton CJ, Ozdemir M and
Ittmann M: Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene. 27:1788–1793. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ichimi T, Enokida H, Okuno Y, Kunimoto R,
Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama
K, et al: Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125:345–352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akao Y, Nakagawa Y and Naoe T:
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 26:311–320.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akao Y, Nakagawa Y, Kitade Y, Kinoshita T
and Naoe T: Downregulation of microRNAs-143 and -145 in B-cell
malignancies. Cancer Sci. 98:1914–1920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi B, Sepp-Lorenzino L, Prisco M, Linsley
P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin
receptor substrate-1 and inhibits the growth of colon cancer cells.
J Biol Chem. 282:32582–32590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sachdeva M, Zhu S, Wu F, Wu H, Walia V,
Kumar S, Elble R, Watabe K and Mo YY: p53 represses c-Myc through
induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA.
106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Larsson E, Fredlund Fuchs P, Heldin J,
Barkefors I, Bondjers C, Genové G, Arrondel C, Gerwins P, Kurschat
C, Schermer B, et al: Discovery of microvascular miRNAs using
public gene expression data: miR-145 is expressed in pericytes and
is a regulator of Fli1. Genome Med. 1:1082009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seoane J, Le HV and Massagué J: Myc
suppression of the p21(Cip1) Cdk inhibitor influences the outcome
of the p53 response to DNA damage. Nature. 419:729–734. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Tang H, Thayanithy V, Subramanian
S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ and Thibodeau SN:
Gene networks and microRNAs implicated in aggressive prostate
cancer. Cancer Res. 69:9490–9497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen X, Gong J, Zeng H, Chen N, Huang R,
Huang Y, Nie L, Xu M, Xia J, Zhao F, et al: MicroRNA145 targets
BNIP3 and suppresses prostate cancer progression. Cancer Res.
70:2728–2738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kwon YJ, Hurst DR, Steg AD, Yuan K, Vaidya
KS, Welch DR and Frost AR: Gli1 enhances migration and invasion via
up-regulation of MMP-11 and promotes metastasis in ERalpha negative
breast cancer cell lines. Clin Exp Metastasis. 28:437–449. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan D, Dai H and Liu JW: Serum levels of
MMP-11 correlate with clinical outcome in Chinese patients with
advanced gastric adenocarcinoma. BMC Cancer. 11:1512011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li DQ, Shang TY, Kim HS, Solomon A,
Lokeshwar BL and Pflugfelder SC: Regulated expression of
collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and
-11 by human corneal epithelial cells. Invest Ophthalmol Vis Sci.
44:2928–2936. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kähäri VM and Saarialho-Kere U: Matrix
metalloproteinases and their inhibitors in tumour growth and
invasion. Ann Med. 31:34–45. 1999.PubMed/NCBI
|
|
39
|
Clark AF: New discoveries on the roles of
matrix metalloproteinases in ocular cell biology and pathology.
Invest Ophthalmol Vis Sci. 39:2514–2516. 1998.PubMed/NCBI
|
|
40
|
Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou
J and Qu P: microRNA-125b inhibits cell migration and invasion by
targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett.
5:829–834. 2013.PubMed/NCBI
|
|
41
|
Moses MA, Wiederschain D, Loughlin KR,
Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix
metalloproteinases in urine of cancer patients. Cancer Res.
58:1395–1399. 1998.PubMed/NCBI
|
|
42
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Valdivia A, Peralta R, Matute-González M,
Garcia Cebada JM, Casasola I, Jiménez-Medrano C, Aguado-Pérez R,
Villegas V, Gonzalez-Bonilla C, Manuel-Apolinar L, et al:
Co-expression of metalloproteinases 11 and 12 in cervical scrapes
cells from cervical precursor lesions. Int J Clin Exp Pathol.
4:674–682. 2011.PubMed/NCBI
|
|
44
|
Pan W, Arnone M, Kendall M, Grafstrom RH,
Seitz SP, Wasserman ZR and Albright CF: Identification of peptide
substrates for human MMP-11 (stromelysin-3) using phage display. J
Biol Chem. 278:27820–27827. 2003. View Article : Google Scholar
|
|
45
|
Rouyer N, Wolf C, Chenard MP, Rio MC,
Chambon P, Bellocq JP and Basset P: Stromelysin-3 gene expression
in human cancer: an overview. Invasion Metastasis. 14:269–275.
1994.PubMed/NCBI
|
|
46
|
Kossakowska AE, Huchcroft SA, Urbanski SJ
and Edwards DR: Comparative analysis of the expression patterns of
metalloproteinases and their inhibitors in breast neoplasia,
sporadic colorectal neoplasia, pulmonary carcinomas and malignant
non-Hodgkin’s lymphomas in humans. Br J Cancer. 73:1401–1408.
1996.PubMed/NCBI
|
|
47
|
Têtu B, Brisson J, Lapointe H and Bernard
P: Prognostic significance of stromelysin 3, gelatinase A, and
urokinase expression in breast cancer. Hum Pathol. 29:979–985.
1998.PubMed/NCBI
|
|
48
|
Nöel AC, Lefebvre O, Maquoi E, VanHoorde
L, Chenard MP, Mareel M, Foidart JM, Basset P and Rio MC:
Stromelysin-3 expression promotes tumor take in nude mice. J Clin
Invest. 97:1924–1930. 1996.PubMed/NCBI
|
|
49
|
Masson R, Lefebvre O, Noël A, Fahime ME,
Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM,
et al: In vivo evidence that the stromelysin-3 metalloproteinase
contributes in a paracrine manner to epithelial cell malignancy. J
Cell Biol. 140:1535–1541. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Noël A, Boulay A, Kebers F, Kannan R,
Hajitou A, Calberg-Bacq CM, Basset P, Rio MC and Foidart JM:
Demonstration in vivo that stromelysin-3 functions through its
proteolytic activity. Oncogene. 19:1605–1612. 2000.PubMed/NCBI
|
|
51
|
Boulay A, Masson R, Chenard MP, El Fahime
M, Cassard L, Bellocq JP, Sautès-Fridman C, Basset P and Rio MC:
High cancer cell death in syngeneic tumors developed in host mice
deficient for the stromelysin-3 matrix metalloproteinase. Cancer
Res. 61:2189–2193. 2001.PubMed/NCBI
|
|
52
|
Wu E, Mari BP, Wang F, Anderson IC, Sunday
ME and Shipp MA: Stromelysin-3 suppresses tumor cell apoptosis in a
murine model. J Cell Biochem. 82:549–555. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Peruzzi D, Mori F, Conforti A, Lazzaro D,
De Rinaldis E, Ciliberto G, La Monica N and Aurisicchio L: MMP11: a
novel target antigen for cancer immunotherapy. Clin Cancer Res.
15:4104–4113. 2009. View Article : Google Scholar : PubMed/NCBI
|
